Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions ...
Adjuvant camrelizumab significantly improves event-free survival in patients with locoregionally advanced nasopharyngeal ...
However, some patients relapse or present with de novo metastatic disease. For those not recently exposed to platinum-based therapies, the standard of care includes gemcitabine, cisplatin, and the ...
The following is a summary of "Early prediction of progression-free survival of patients with locally advanced nasopharyngeal ...
Chinese scientists have developed a new treatment for nasopharyngeal carcinoma that helps patients live longer and have a better quality of life compared with traditional therapies that often cause ...
Phase III DIPPER trial shows that adjuvant camrelizumab administered after induction-concurrent chemoradiotherapy ...
A recent international study led by archaeologist Kamila Braulińska from the University of Warsaw challenged previous claims ...
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...
TAIPEI (Taiwan News) — A study by Chang Gung Memorial Hospital has discovered that removing the amino acid asparagine from ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback